Charles River Laboratories (CRL) Tops Q4 EPS by 23c; Guides FY23 EPS Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $353.05 +4.29%
EPS Growth %: +22.2%
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
INM, TRI, CRVL, More
EPS Growth %: +22.2%
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.98, $0.23 better than the analyst estimate of $2.75. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.04 billion.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $9.70-$10.90. Charles River Laboratories sees FY2023 revenue of $11.37 billion. Revenue growth, reported up 1.5-4.5%. Sees Revenue growth, organic up 4.5-7.5%.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Upstart Holdings (UPST) Tops Q3 EPS by 12c ; Offers Guidance
- Apple shares slip amid guidance for tightening margins, slowing services growth
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
